Ending Gender Inequality in Cardiovascular Clinical Trial Leadership - Université de Lorraine Access content directly
Journal Articles Journal of the American College of Cardiology Year : 2021

Ending Gender Inequality in Cardiovascular Clinical Trial Leadership

Padma Kaul
  • Function : Author
Monica R Shah
  • Function : Author
James Revkin
  • Function : Author

Abstract

Women are under-represented as leaders of cardiovascular randomized controlled trials, representing 1 in 10 lead authors of cardiovascular trials published in high-impact journals. Although the proportion of cardiovascular specialists who are women has increased in recent years, the proportion of cardiovascular clinical trialists who are women has not. This gap, underpinned by systemic sexism, has not been adequately addressed. The benefits of diverse randomized controlled trial leadership extend to patients and professionals. In this position statement, we present strategies adopted by some organizations to end gender inequality in research leadership. We offer an actionable roadmap for early-career researchers, scientists, academic institutions, professional societies, trial sponsors, and journals to follow, with the goal of harnessing the strength of women and under-represented groups as research leaders and facilitating a just culture in the cardiovascular clinical trial enterprise.
Fichier principal
Vignette du fichier
34112322.pdf (1.25 Mo) Télécharger le fichier
34112322.docx (2.83 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03721322 , version 1 (12-07-2022)

Identifiers

Cite

Harriette G.C. van Spall, Anuradha Lala, Thomas F Deering, Barbara Casadei, Faiez Zannad, et al.. Ending Gender Inequality in Cardiovascular Clinical Trial Leadership. Journal of the American College of Cardiology, 2021, 77 (23), pp.2960-2972. ⟨10.1016/j.jacc.2021.04.038⟩. ⟨hal-03721322⟩
13 View
100 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More